Accelerative effect of leflunomide on recovery from hepatic fibrosis involves TRAIL-mediated hepatic stellate cell apoptosis

Life Sciences

Volumn 84, Issue 15-16, 2009, Pages 552-557

  Tang, Xiaoming ^a   Yang, Juntao ^b   Li, Jun ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Hepatic fibrosis; Hepatic stellate cells; Kupffer cells; Leflunomide; TRAIL

Indexed keywords

CARBON TETRACHLORIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEFLUNOMIDE; SMALL INTERFERING RNA; TERIFLUNOMIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; KUPFFER CELL; LIVER CELL; LIVER FIBROSIS; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; STELLATE CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; HEPATIC STELLATE CELLS; ISOXAZOLES; KUPFFER CELLS; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

RATTUS;

EID: 62749084923     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2009.01.017     Document Type: Article

References (38)

1. Afford S.C., and Adams D.H. Following the TRAIL from hepatitis C virus and alcohol to fatty liver. Gut 54 11 (2005) 1518-1520
2. Alexander D., Friedrich B., Abruzzese T., Gondolph-Zink B., Wulker N., and Aicher W.K. The active form of leflunomide, HMR1726, facilitates TNF-alpha and IL-17 induced MMP-1 and MMP-3 expression. Cellular Physiology Biochemistry 17 1-2 (2006) 69-78
3. Bataller R., and Brenner D.A. Hepatic stellate cells as a target for the treatment of liver fibrosis. Seminars in Liver Disease 21 3 (2001) 437-451
4. Benyon R.C., and Arthur M.J. Extracellular matrix degradation and the role of hepatic stellate cells. Seminars in Liver Disease 21 3 (2001) 373-384
5. 2, matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes. Rheumatology 42 1 (2003) 89-96
6. Choo-Kang B.S., Hutchison S., Nickdel M.B., Bundick R.V., Leishman A.J., Brewer J.M., McInnes I.B., and Garside P. TNF-blocking therapies: an alternative mode of action?. Trends in Immunology 26 10 (2005) 518-522
7. Davis J.P., Cain G.A., Pitts W.J., Magolda R.L., and Copeland R.A. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 35 4 (1996) 1270-1273
8. Duffield J.S., Forbes S.J., Constandinou C.M., Clay S., Partolina M., Vuthoori S., Wu S., Lang R., and Iredale J.P. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. The Journal of Clinical Investigation 115 1 (2005) 56-65
9. Fischer R., Cariers A., Reinehr R., and Häussinger D. Caspase 9-dependent killing of hepatic stellate cells by activated Kupffer cells. Gastroenterology 123 3 (2002) 845-861
10. Fox R.I., Herrmann M.L., Frangou C.G., Wahl G.M., Morris R.E., Strand V., and Kirschbaum B.J. Mechanism of action for leflunomide in rheumatoid arthritis. Clinical Immunology 93 3 (1999) 198-208
11. Friedman S.L. Mac the knife? Macrophages - the double-edged sword of hepatic fibrosis. The Journal of Clinical Investigation 115 1 (2005) 29-32
12. Friedman S.L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiological Reviews 88 1 (2008) 125-172
13. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 134 6 (2008) 1655-1669
14. Friedman S.L., and Arthur M.J. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. The Journal of Clinical Investigation 84 6 (1989) 1780-1785
15. Friedman S.L., and Roll F.J. Isolation and culture of hepatic lipocytes, Kupffer cells, and sinusoidal endothelial cells by density gradient centrifugation with Stractan. Analytical Biochemistry 161 1 (1987) 207-218
16. Geerts A., Lazou J.M., De Bleser P., and Wisse E. Tissue distribution, quantitation and proliferation kinetics of fat-storing cells in carbon tetrachloride-injured rat liver. Hepatology 13 6 (1991) 1193-1202
17. Groth C.G., Tibell A., Wennberg L., and Korsgren O. Xenoislet transplantation: experimental and clinical aspects. Journal of Molecular Medicine 77 1 (1999) 153-154
18. Guo J., and Friedman S.L. Hepatic fibrogenesis. Seminars in Liver Disease 27 4 (2007) 413-426
19. Ikejima K., Enomoto N., Seabra V., Ikejima A., Brenner D.A., and Thurman R.G. Pronase destroys the lipopolysaccharide receptor CD14 on Kupffer cells. The American Journal of Physiology 276 (1999) 591-598
20. Imose M., Nagaki M., Kimura K., Takai S., Imao M., Naiki T., Osawa Y., Asano T., Hayashi H., and Moriwaki H. Leflunomide protects from T-cell-mediated liver injury in mice through inhibition of nuclear factor kappaB. Hepatology 40 5 (2004) 1160-1169
21. Iredale J.P. Hepatic stellate cell behavior during resolution of liver injury. Seminars in Liver Disease 21 3 (2001) 427-436
22. Iredale J.P., Benyon R.C., Pickering J., McCullen M., Northrop M., Pawley S., Hovell C., and Arthur M.J. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. The Journal of Clinical Investigation 102 3 (1998) 538-549
23. Issa R., Williams E., Trim N., Kendall T., Arthur M.J., Reichen J., Benyon R.C., and Iredale J.P. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 48 4 (2001) 548-557
24. Issa R., Zhou X., Trim N., Millward-Sadler H., Krane S., Benyon C., and Iredale J. Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CCl4-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration. The FASEB Journal 17 1 (2003) 47-49
25. Issa R., Zhou X., Constandinou C.M., Fallowfield J., Millward-Sadler H., Gaca M.D., Sands E., Suliman I., Trim N., Knorr A., Arthur M.J., Benyon R.C., and Iredale J.P. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 126 7 (2004) 1795-1808
26. Leger D.Y., Liagre B., and Beneytout J.L. Low dose leflunomide activates PI3K/Akt signalling in erythroleukemia cells and reduces apoptosis induced by anticancer agents. Apoptosis 11 10 (2006) 1747-1760
27. Manna S.K., and Aggarwal B.B. Immunosuppressive leflunomide metabolite (A771726) blocks TNF-dependent nuclear factor-κB activation and gene expression. Journal of Immunology 162 4 (1999) 2095-2102
28. Manna S.K., Mukhopadhyay A., and Aggarwal B.B. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. Journal of Immunology 165 10 (2000) 5962-5969
29. Migita K., Miyashita T., Maeda Y., Nakamura M., Yatsuhashi H., Ishibashi H., and Eguchi K. An active metabolite of leflunomide, A771726, inhibits the production of serum amyloid A protein in human hepatocytes. Rheumatology 44 4 (2005) 443-448
30. Pinzani M., and Marra F. Cytokine receptors and signaling in hepatic stellate cells. Seminars in Liver Disease 21 3 (2001) 397-416
31. Ravi R., Bedi G.C., Engstrom L.W., Zeng Q., Mookerjee B., Gélinas C., Fuchs E.J., and Bedi A. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nature Cell Biology 3 4 (2001) 409-416
32. Saxena N.K., Titus M.A., Ding X., Floyd J., Srinivasan S., Sitaraman S.V., and Anania F.A. Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation. The FASEB Journal 18 13 (2004) 1612-1614
33. Shiratori Y., Geerts A., Ichida T., Kawase T., and Wisse E. Kupffer cells from CCl4-induced fibrotic livers stimulate proliferation of fat-storing cells. Journal of Hepatology 3 3 (1986) 294-303
34. Si H.F., Li J., Lü X.W., and Jin Y. Suppressive effects of leflunomide on leptin-induced collagen I production involved in hepatic stellate cell proliferation. Experimental Biology and Medicine (Maywood, N.J.) 232 3 (2007) 427-436
35. Vrenken T.E., Buist-Homan M., Kalsbeek A.J., Faber K.N., and Moshage H. The active metabolite of leflunomide, A771726, protects rat hepatocytes against bile acid-induced apoptosis. Journal of Hepatology 49 5 (2008) 799-809
36. Wright M.C., Issa R., Smart D.E., Trim N., Murray G.I., Primrose J.N., Arthur M.J., Iredale J.P., and Mann D.A. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 121 3 (2001) 685-698
37. Xu X., Williams J.W., Bremer E.G., Finnegan A., and Chong A.S. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. The Journal of Biological Chemistry 270 21 (1995) 12398-12403
38. Yao H.W., Li J., Chen J.Q., and Xu S.Y. Inhibitory effect of leflunomide on hepatic fibrosis induced by CCl4 in rats. Acta Pharmacologica Sinica 25 7 (2004) 915-920